The development of bispecific antibodies and their applications in tumor immune escape

During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaolong, Yang, Yuanyuan, Fan, Dongmei, Xiong, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414286/
https://www.ncbi.nlm.nih.gov/pubmed/28469973
http://dx.doi.org/10.1186/s40164-017-0072-7
_version_ 1783233343010111488
author Zhang, Xiaolong
Yang, Yuanyuan
Fan, Dongmei
Xiong, Dongsheng
author_facet Zhang, Xiaolong
Yang, Yuanyuan
Fan, Dongmei
Xiong, Dongsheng
author_sort Zhang, Xiaolong
collection PubMed
description During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape.
format Online
Article
Text
id pubmed-5414286
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54142862017-05-03 The development of bispecific antibodies and their applications in tumor immune escape Zhang, Xiaolong Yang, Yuanyuan Fan, Dongmei Xiong, Dongsheng Exp Hematol Oncol Review During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape. BioMed Central 2017-05-02 /pmc/articles/PMC5414286/ /pubmed/28469973 http://dx.doi.org/10.1186/s40164-017-0072-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhang, Xiaolong
Yang, Yuanyuan
Fan, Dongmei
Xiong, Dongsheng
The development of bispecific antibodies and their applications in tumor immune escape
title The development of bispecific antibodies and their applications in tumor immune escape
title_full The development of bispecific antibodies and their applications in tumor immune escape
title_fullStr The development of bispecific antibodies and their applications in tumor immune escape
title_full_unstemmed The development of bispecific antibodies and their applications in tumor immune escape
title_short The development of bispecific antibodies and their applications in tumor immune escape
title_sort development of bispecific antibodies and their applications in tumor immune escape
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414286/
https://www.ncbi.nlm.nih.gov/pubmed/28469973
http://dx.doi.org/10.1186/s40164-017-0072-7
work_keys_str_mv AT zhangxiaolong thedevelopmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT yangyuanyuan thedevelopmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT fandongmei thedevelopmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT xiongdongsheng thedevelopmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT zhangxiaolong developmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT yangyuanyuan developmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT fandongmei developmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape
AT xiongdongsheng developmentofbispecificantibodiesandtheirapplicationsintumorimmuneescape

Ejemplares similares